Why us, why this strategy, and why now?

Why us, and why the answer is almost never a biography

The question is not who you are. It is what about you produces different decisions, and how a stranger could verify that from outside.

ILPA's own emerging manager publication, Seven Habits of Highly Effective Emerging Managers, published in November 2017, puts the underlying constraint plainly from the allocator's side: a lack of track record for emerging teams means investors have to rely on less traditionally quantitative data, including reference checks and back-channelling with people who are not on the manager's own reference list. Read from your side, that means the answer to why us is being assembled about you whether or not you supply it, so the useful version is the one that matches what those people would say.

• Decisions, not roles. Companies you chose, when, at what stage, with your reasoning recorded at the time.
• Access, not network size. Who brings you deals before a generalist sees them, named as channels rather than described as relationships.
• Domain depth, evidenced by what you know that a generalist does not, and by the specific people who treat you as a peer in it.
• Founder relationships, evidenced by founders who will describe how you behaved when a company was struggling rather than when it was working.
• Team composition, meaning who decides, who sources, who runs operations, and what happens when two of you disagree. The same ILPA piece notes that experienced limited partners often read team dynamics in the first interaction, and asks the two questions a manager should be able to answer: how will you challenge each other, and what are the checks and balances.

Why this strategy, stated as a boundary rather than a preference

Define both what you invest in and where you draw the boundary. Stage, geography, check size, ownership and exclusions help an LP understand the strategy and test its construction.

The four elements of a defensible answer are the boundary, the mechanism, the arithmetic, and the disconfirming case.

• The boundary. Stage, sector, geography, cheque size, and ownership, stated tightly enough that an allocator could reject a deal as off-thesis without asking you.
• The mechanism. The reason that boundary produces a return rather than a preference: what you see, what you are chosen for, and what you can do for a company that others cannot.
• The arithmetic. Ownership, position count, reserves, and pacing that reconcile with your fund size, since a strategy the portfolio math contradicts is not a strategy. Blueprint's page on explaining portfolio construction covers what an allocator checks here.
• The disconfirming case. What would make you wrong, and what you would do about it. Managers who can answer this are rarer than they should be, and it lands harder than any conviction statement.

Why now, without manufacturing urgency

A timing argument needs a real change in the market or the firm. If no special window exists, explain why the strategy is relevant now without manufacturing urgency.

Three kinds of timing answer are defensible, and one is not.

• Structural change you can point at. A regulatory shift, a technology reaching production readiness, a cost curve crossing a threshold, or a buyer category that did not exist three years ago. Name the change and name what you can see because of it.
• Your own readiness. The access, the team, and the evidence arrived at this point, which is a real answer and an underused one.
• Capacity and access. There is a window in which a strategy can be run at your size before it becomes crowded or before ownership gets harder, which is a claim about your market rather than about the allocator's calendar.
• Not defensible: scarcity language about your own raise. A closing date is a fact about your fund, not a reason for anyone to invest, and Blueprint's page on why an LP should invest now covers the difference between real and artificial urgency, including the promotional-claim rules that make some framings a compliance question rather than a taste question.

The narrative worksheet

One row per claim. A claim with an empty evidence column is not ready to be said out loud, and the discipline of filling the third column is what converts a pitch into a position.

• Claim. One sentence, in the words you would actually use in a meeting.
• Evidence. The specific, checkable thing behind it: a deal, a date, a named channel, a founder who will confirm it, a published fact about the market.
• Who would confirm it. A person, not a category. If nobody would, the claim is an opinion and belongs labelled as one.
• What it does not prove. The honest limit, written by you before an allocator writes it for you.
• Where it lives. Deck, teaser, data room, or conversation only. Some of your best evidence is confidential and belongs in diligence rather than in a public document.

Weak framing against evidence-backed framing

The same underlying fact, said two ways. The left-hand version is what most first decks contain.

• Weak: we have deep networks in the sector. Evidence-backed: eleven of our last fifteen deals came through four named operator communities, and here is the conversion rate from each.
• Weak: we invest in overlooked founders. Evidence-backed: we invest at pre-seed in founders who are technical leads at companies in this specific industry, a group we reach through a programme we have run for three years.
• Weak: we add real value post-investment. Evidence-backed: three founders will tell you what we did in the six months after their round, including the one whose company did not make it.
• Weak: the market is at an inflection point. Evidence-backed: this regulation took effect last year, which is why the buyer we sell into now has a budget line that did not exist.
• Weak: we have a differentiated thesis. Evidence-backed: here is what we will not invest in, and here are two deals we passed on that other funds in our category took.

What limited partners are testing across all three parts

The three questions are one question asked three ways: can this be underwritten?

• Is the evidence attributable to this team rather than to a firm they used to work at?
• Does the strategy have a boundary, and does the portfolio arithmetic sit inside it?
• Is the timing claim about the market, or about the manager's fundraising calendar?
• Would the references, including the ones the manager did not name, tell the same story?
• Is the manager candid about what is weak, or does the narrative have no soft edges at all?

What this narrative does not prove

A strong three-part answer gets a second meeting. It does not substitute for the evidence file behind it, and an allocator who likes the story will immediately start testing whether it is true.

The worksheet and the framing examples on this page are Blueprint's own. The external material is either an institutional publication, cited with its date, or practitioner commentary, labelled as such.

This page is educational and general. It is not legal, tax, securities, or investment advice, and claims about performance, timing, or market conditions in fundraising materials can carry regulatory obligations in the jurisdictions where you market.